The real Avandia story – Glaxo knew the drug was a killer in 1999

This from CBS bnet:
GlaxoSmithKline (GSK)’s decision to settle most of the litigation over its Avandia diabetes drug for $460 million means that former CEO Jean-Pierre Garnier will never testify about why he sent an email in 1999 raising concerns that his diabetes drug had “a high number of CV [cardiovascular] deaths while other glitazones [similar drugs] did not.” Avandia had only been on the market for one month at the time the email was sent, according to a deposition transcript in which the email was read aloud.

The email is one reason why GSK decided today — 11 years after Garnier raised the issue with his staff — to settle about 10,000 cases for $46,000 apiece. The FDA is reviewing the drug’s record for heart attacks and other cardiovascular problems; it will probably be withdrawn from the market or the terms of its use will be severely restricted.

So Garnier and Glaxo knew in 1999 that Avandia was a killer – but it didn’t stop them pushing the drug for 11 more years.

The next thing we need to know is just what data did Glaxo supply in order to get Avandia licenced by the MHRA and FDA?

How did Glaxo manage to pull the wool over the regulators’ eyes?

I’m just asking….


2 Responses to “The real Avandia story – Glaxo knew the drug was a killer in 1999”

  1. Back In The Frame : Avandia Gets Pulled By Europe « GSK : Licence To (K) ill Says:

    […] out to Bob Fiddaman, all the lone bloggers and patient advocates out there, and also of course to Seroxat Secrets. You’re all doing a great service guys. Well […]

  2. Lynn Says:

    companies sending research to less expensive countries.
    “A report by the Department of Health and Human Services’ Office of the Inspector General last year said that between 40 percent and 65 percent of clinical trials of products regulated by the Food and Drug Administration are now conducted abroad.”
    “Big pharmaceutical companies are also increasingly offshoring their research to cut costs. The former CEO of GlaxoSmithKline told the Harvard Business Review in 2008 that if a company with 60,000 patients in clinical trials moved 50 percent of its trials to low-cost countries, it would save $600 million a year.”

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: